Disorders of Blood Flow: Hyperlipidemia, Atherosclerosis, and Vascular Pathology

Disorders of Blood Flow

Introduction

Disorders of blood flow encompass a range of pathologies affecting the arteries and veins, often leading to significant morbidity and mortality. This study guide covers the major types of blood flow disorders, including hyperlipidemia, atherosclerosis, arterial and venous diseases, and their clinical implications.

Hyperlipidemia & Atherosclerosis

Cholesterol and Triglyceride Laboratory Values

Cholesterol and triglyceride levels are key indicators of cardiovascular risk. Laboratory assessment is essential for diagnosis and management.

Analyte	Concentration (mg/dL)	Interpretation
Total Cholesterol	<200	Optimal
Total Cholesterol	200-239	Borderline high
Total Cholesterol	>=240	High
LDL Cholesterol	<100	Optimal
LDL Cholesterol	100-129	Above optimal
LDL Cholesterol	130-159	Borderline high
LDL Cholesterol	160-189	High
LDL Cholesterol	>=190	Very high
HDL Cholesterol	<40	Low
HDL Cholesterol	>=60	High (protective)
Triglycerides	<150	Normal
Triglycerides	150-199	Borderline high
Triglycerides	200-499	High
Triglycerides	>=500	Very high

• HDL is considered "good cholesterol" due to its role in reverse cholesterol transport.

Lipid Laboratory Measurement

• Blood samples should ideally be collected in the fasting state (at least 12 hours) to clear chylomicrons and IDL from the blood.

• In the non-fasting state, only total cholesterol and HDL are considered accurate.

• LDL-C is commonly calculated using the Friedewald equation:

$\text{LDL-C (mg/dL)} = \text{Total Cholesterol} - \text{HDL-C} - \left(\frac{\text{Triglycerides}}{5}\right)$

• VLDL is approximated by dividing triglycerides by 5.

Risk Factors for Atherosclerosis

Atherosclerosis is a chronic inflammatory disease of the arterial wall, leading to plaque formation and vascular obstruction.

Modifiable (Secondary) Risk Factor	Mechanism
Hypercholesterolemia (e.g., diet)	↑LDL: Substrate for plaque; ↓HDL: Cholesterol removal from circulation
Obesity	Proinflammatory cytokine release from adipose tissue
Hypertension (HTN)	Shear stress/damage to endothelium
Diabetes	↓LDL removal from circulation, glycation of proteins
Cigarette smoking	Endothelial damage
Hypothyroidism	↓LDL receptor production
Lipoprotein A/homocysteine	↑Oxidation of LDL
Nonmodifiable (Primary) Risk Factor	Mechanism
Male gender	Estrogen increases LDL receptors (protective in females)
Age, family history	Genetic predisposition

Types and Causes of Hyperlipidemia

• Primary (genetic) hyperlipidemia: Most commonly familial hypercholesterolemia (type 2a), due to LDL receptor dysfunction.

• Secondary hyperlipidemia: Caused by diet, medications (beta-blockers, glucocorticoids, antipsychotics, estrogen/progestin), obesity, diabetes, hypothyroidism, nephrotic syndrome, and liver disease.

Clinical Manifestations:

• Xanthomas (cholesterol deposits in skin/tendons)

• Pancreatitis (especially with hypertriglyceridemia)

• Atherosclerosis and its complications (coronary artery disease, stroke, peripheral arterial disease, aneurysms, kidney disease)

Treatment of Hyperlipidemia

• Lifestyle modifications: diet (limit saturated fats), exercise

• Drug therapy:

  • Statins: Inhibit cholesterol synthesis

  • Bile acid resins: Bind bile acids in the gut

  • Niacin: Inhibits VLDL synthesis, increases HDL

  • Fibrates: Increase triglyceride clearance

  • Ezetimibe: Inhibits intestinal cholesterol absorption

  • Lomitapide: Inhibits VLDL synthesis

  • PCSK9 inhibitors: Prevent LDL receptor degradation

Arterial Disorders

Peripheral Artery Disease (PAD)

PAD is a manifestation of systemic atherosclerosis, most commonly affecting the femoral and popliteal arteries.

• Risk increases with age and cardiovascular risk factors.

• Symptoms are often absent until significant occlusion occurs.

• Intermittent claudication: Ischemic pain or fatigue with exertion, relieved by rest.

• Advanced disease: pain at rest, ulcerations, necrosis, gangrene, muscle wasting, thin skin, weak/absent pulses.

Diagnosis:

• Clinical assessment and measurement of the Ankle-Brachial Index (ABI):

$\text{ABI} = \frac{\text{Ankle systolic BP}}{\text{Brachial systolic BP}}$

• ABI < 0.9 is consistent with significant arterial occlusion.

Treatment:

• Lifestyle modification and exercise (walking 30-45 min, 3x/week)

• Risk factor management

• Antiplatelet agents (aspirin, clopidogrel, dipyridamole, cilostazol)

Aneurysms and Dissections

Aneurysms are localized dilations of blood vessels, most commonly arteries. Dissections involve a tear in the vessel wall, allowing blood to separate the layers.

• Types of aneurysms: Berry (saccular), fusiform (circumferential), saccular (localized bulge), and dissection (tear in intima).

• Common causes: Atherosclerosis, hypertension, congenital defects, trauma, infection.

Aortic Aneurysms:

• Thoracic: substernal, neck, or back pain, dyspnea, hoarseness, venous distension.

• Abdominal: pulsating abdominal mass, pain, thrombus formation, distal emboli.

• Rupture risk increases with size (>5 cm diameter = high risk).

• Treatment: surgical repair for large or symptomatic aneurysms.

Aortic Dissection:

• Most common in the ascending aorta.

• Sudden, severe pain (anterior chest or back), possible paralysis, syncope, heart failure, limb ischemia.

• Treatment: blood pressure control (beta-blockers, vasodilators), surgical intervention.

Venous Disorders

Venous Thromboembolism (VTE)

VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Thrombi most commonly form in the lower extremities, especially around vein valves.

• Superficial veins: Lower risk of PE.

• Deep veins: Higher risk of PE and chronic venous insufficiency.

Risk Factors (Virchow's Triad):

• Stasis (immobility, heart failure, shock, obesity, venous catheterization)

• Hypercoagulability (cancer, antiphospholipid syndrome, inherited thrombophilias, oral contraceptives)

• Vascular trauma (surgery, trauma, venous catheterization)

Pathophysiology: Inflammation and coagulation cascade activation lead to thrombus formation, often involving leukocytes, platelets, and neutrophil extracellular traps (NETs).

Clinical Manifestations:

• Often asymptomatic

• Unilateral pain, tenderness, swelling, redness

• Complications: pulmonary embolism, post-thrombotic syndrome

Laboratory Assessment:

• D-dimer: degradation product of cross-linked fibrin; <500 ng/mL is considered negative for VTE (high sensitivity, low specificity)

Prevention:

• Early ambulation, pneumatic compression devices, compression stockings, prophylactic anticoagulation (heparin, low molecular weight heparin)

Treatment:

• Thrombolytic therapy (tPA) in select cases

• Anticoagulant therapy: warfarin, heparin, low molecular weight heparin, direct thrombin inhibitors (dabigatran), factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, fondaparinux)

Chronic Venous Disease

Chronic venous disease results from increased venous pressure, most commonly in the lower extremities, leading to compromised venous return and inflammation.

• Risk factors: age, female gender, obesity, sedentary lifestyle, prolonged standing/sitting, smoking, family history, height

• Pathophysiology: venous wall stress, hypoxia, wall remodeling, increased permeability, leukocyte and RBC extravasation, hemosiderin deposition, proinflammatory cytokine release, collagen synthesis, decreased elastin

Clinical Manifestations:

• Varicose veins (dilated, tortuous superficial veins, especially saphenous veins)

• Edema, discomfort, heaviness, tenderness, skin changes (lipodermatosclerosis, brown pigmentation, stasis dermatitis)

• Venous ulcers (especially around the ankles)

Varicose Veins: Incompetent valves and impaired muscle pump function lead to venous dilation and tortuosity, most commonly affecting the saphenous veins.

Chronic Venous Insufficiency: Characterized by varicose veins, tissue edema, leg pain, heaviness, tenderness, intermittent claudication, and cutaneous changes. Accounts for 80% of venous ulcers.